Round: Venture
Description: San Francisco-based Verily develops tools and devices to collect and analyze health data to research and manage diseases. Founded by Andrew Conrad, Brian Otis, Jessica Mega in 2015, Verily has now raised a total of $2.5B in total equity funding and is backed by investors that include Silver Lake, Temasek Holdings, Alphabet, and Ontario Teachers’ Pension Plan.
Investors in the round: Alphabet, Ontario Teachers’ Pension Plan, Silver Lake, Temasek Holdings
Industry: Enterprise Software, Health Care, Information Technology, Software
Founders: Andrew Conrad, Brian Otis, Jessica Mega
Founding year: 2015
Total equity funding raised: $2.5B The TechWatch Media Group audience is driving progress and innovation on a global scale. With its regional media properties (NYC Tech, LA Tech, London Tech, Paris Tech, Boston Tech) TechWatch Media Group is the highway for technology and entrepreneurship. There are a number of options to reach this audience of the wo
AlleyWatch
Verily
Verily develops tools and devices to collect and analyze health data to research and manage diseases. Founded by Andrew Conrad, Brian Otis, and Jessica Mega in 2015, Verily is backed by investors that include Silver Lake, Temasek Holdings, Alphabet, and Ontario Teachers’ Pension Plan and is headquartered in San Francisco.
FOUNDED:2015
FOUNDERS:Andrew Conrad, Brian Otis, Jessica Mega
Justin Sullivan/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Verily, Alphabet s secretive healthcare moonshot, is overhauling its leadership structure and cutting down on CEO Andy Conrad s direct reports.
A new chief operating officer took over a lot of Conrad s responsibilities. There s also a new tech chief, and the company is looking for chief marketing, revenue, and information officers.
Meanwhile, Verily in December raised $700 million in a new round of funding that it said would be used to expand its star commercial businesses.
During an all-hands meeting in November, Verily Life Sciences CEO Andy Conrad announced that the company would be run differently.